These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37097712)

  • 1. van Rhee F, Rosenthal A, Kanhai K, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022;6(16):4773-4781.
    Blood Adv; 2023 Apr; 7(8):1604-1605. PubMed ID: 37097712
    [No Abstract]   [Full Text] [Related]  

  • 2. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
    van Rhee F; Rosenthal A; Kanhai K; Martin R; Nishimura K; Hoering A; Fajgenbaum DC
    Blood Adv; 2022 Aug; 6(16):4773-4781. PubMed ID: 35793409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
    van Rhee F; Casper C; Voorhees PM; Fayad LE; Gibson D; Kanhai K; Kurzrock R
    Lancet Haematol; 2020 Mar; 7(3):e209-e217. PubMed ID: 32027862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
    Morra DE; Pierson SK; Shilling D; Nemat S; Appiani C; Guilfoyle M; Tendler C; van Rhee F; Fajgenbaum DC
    Br J Haematol; 2019 Jan; 184(2):232-241. PubMed ID: 30203839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
    van Rhee F; Rossi JF; Simpson D; Fosså A; Dispenzieri A; Kuruvilla J; Goh YT; Cho SG; Capra M; Liu T; Casper C; Cavet J; Wong RS
    Br J Haematol; 2021 Jan; 192(1):e28-e31. PubMed ID: 33128769
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation.
    Ostrowska B; Szymczyk A; Olszewska-Szopa M; Romejko-Jarosińska J; Domańska-Czyż K; Dąbrowska-Iwanicka A; Tomczak W; Rybski S; Hus M; Wróbel T; Walewski J
    Leuk Lymphoma; 2021 Dec; 62(12):3031-3034. PubMed ID: 34159888
    [No Abstract]   [Full Text] [Related]  

  • 7. Siltuximab for Multicentric Castleman Disease-Letter.
    Teipel R; Ordemann R; Proske U; Dietrich F; Mende M; Ehninger G; Kroschinsky F; Platzbecker U
    Clin Cancer Res; 2015 Oct; 21(20):4740. PubMed ID: 26473194
    [No Abstract]   [Full Text] [Related]  

  • 8. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
    van Rhee F; Casper C; Voorhees PM; Fayad LE; van de Velde H; Vermeulen J; Qin X; Qi M; Tromp B; Kurzrock R
    Oncotarget; 2015 Oct; 6(30):30408-19. PubMed ID: 26327301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
    Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani SZ; van de Velde H; Qin X; Puchalski TA; Hall B; Reddy M; Qi M; van Rhee F
    Clin Cancer Res; 2013 Jul; 19(13):3659-70. PubMed ID: 23659971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
    Tonialini L; Bonfichi M; Ferrero S; Malipiero G; Nozza A; Argnani L; Zinzani PL
    Hematol Oncol; 2018 Oct; 36(4):689-692. PubMed ID: 30074630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Idiopathic Castleman Disease.
    van Rhee F; Greenway A; Stone K
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):89-106. PubMed ID: 29157622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances.
    Lang E; van Rhee F
    Blood Rev; 2024 Mar; 64():101161. PubMed ID: 38087716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
    van Rhee F; Wong RS; Munshi N; Rossi JF; Ke XY; Fosså A; Simpson D; Capra M; Liu T; Hsieh RK; Goh YT; Zhu J; Cho SG; Ren H; Cavet J; Bandekar R; Rothman M; Puchalski TA; Reddy M; van de Velde H; Vermeulen J; Casper C
    Lancet Oncol; 2014 Aug; 15(9):966-74. PubMed ID: 25042199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.
    Min GJ; Jeon YW; Park SS; Park S; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
    Korean J Intern Med; 2021 Mar; 36(2):424-432. PubMed ID: 32088937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Siltuximab: first global approval.
    Markham A; Patel T
    Drugs; 2014 Jul; 74(10):1147-52. PubMed ID: 24958337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Interleukin-6 in Castleman Disease.
    Yoshizaki K; Murayama S; Ito H; Koga T
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):23-36. PubMed ID: 29157617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
    Lust H; Gong S; Remiker A; Rossoff J
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of siltuximab.
    Davis CC; Shah KS; Lechowicz MJ
    Curr Oncol Rep; 2015 Jul; 17(7):29. PubMed ID: 25986720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indolent T-Lymphoblastic Proliferation in Idiopathic Multicentric Castleman Disease.
    Karki NR; Arfa AS; Savage N; Kutlar A
    Acta Haematol; 2022; 145(2):214-220. PubMed ID: 34818661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease.
    Pierson SK; Katz L; Williams R; Mumau M; Gonzalez M; Guzman S; Rubenstein A; Oromendia AB; Beineke P; Fosså A; van Rhee F; Fajgenbaum DC
    Nat Commun; 2022 Nov; 13(1):7236. PubMed ID: 36433996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.